This NDC is on FDA's drug shortage list (posted Mar 1, 2017)
Reported reason: Other
Product Information
SODIUM BICARBONATE 8.4% VIAL is a generic product labeled by Hospira Inc., priced at $0.1540 per ML under NDC 00409662535. Its NADAC has been published 211 times since May 26, 2021.
FDA first approved this application on Sep 26, 2017. Its Orange Book therapeutic-equivalence code is AP.
Strength
84 mg/mL
Manufacturer
Hospira Inc.NDC
00409662535
Classification
Generic
Dosage Form
INJECTION, SOLUTION
Route
INTRAVENOUS
Effective Date
7/22/2026
Active Ingredients
SODIUM BICARBONATEApproval Type
Generic (ANDA)
FDA Application
ANDA202432FDA Approved
9/26/2017
TE Code
AP
On Market Since
3/1/2021
Pharmacological Classes
Price Statistics
The NADAC for SODIUM BICARBONATE 8.4% VIAL has been published 211 times since May 26, 2021, and over the history we have for it it has declined 13.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1540 per ML |
|---|---|
| All-time high | $0.2082 (Apr 16, 2025) |
| All-time low | $0.1540 (Apr 22, 2026) |
| 52-week high | $0.1721 |
| 52-week low | $0.1540 |
| Median price | $0.1708 |
| Average price | $0.1714 |
| Largest weekly change | +11.4% (Feb 19, 2025) |
| Weeks tracked | 211 |
| Tracking since | May 26, 2021 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hospira Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
SODIUM BICARBONATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Osmotic Laxative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SODIUM BICARBONATE 8.4% VIAL?
The current National Average Drug Acquisition Cost (NADAC) for SODIUM BICARBONATE 8.4% VIAL, manufactured by Hospira Inc., is $0.1540 per ML (NDC 00409662535), effective Sep 30, 2026.
How has the price of SODIUM BICARBONATE 8.4% VIAL changed over time?
Over the history we have for it, the NADAC for SODIUM BICARBONATE 8.4% VIAL has declined 13.1%. It has been tracked across 211 weekly CMS publications since May 26, 2021.
What are the highest and lowest recorded NADAC prices for SODIUM BICARBONATE 8.4% VIAL?
Since May 26, 2021, the NADAC for SODIUM BICARBONATE 8.4% VIAL has ranged from a low of $0.1540 (Apr 22, 2026) to a high of $0.2082 (Apr 16, 2025), with a median of $0.1708 per ML.
Are there cheaper alternatives to SODIUM BICARBONATE 8.4% VIAL?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as SODIUM BICARBONATE 8.4% VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures SODIUM BICARBONATE 8.4% VIAL?
SODIUM BICARBONATE 8.4% VIAL (NDC 00409662535) is labeled by Hospira Inc., and CMS classifies it as a generic product.
Is SODIUM BICARBONATE 8.4% VIAL in shortage?
Yes — NDC 00409662535 is currently listed in FDA's drug shortage database (posted Mar 1, 2017). Reported reason: Other.